Metabolic dysfunction-associated fatty liver disease in people living with HIV.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
06 06 2023
06 06 2023
Historique:
received:
04
01
2023
accepted:
05
04
2023
medline:
8
6
2023
pubmed:
7
6
2023
entrez:
6
6
2023
Statut:
epublish
Résumé
The prevalence of metabolic risk factors and non-alcoholic fatty liver disease (NAFLD) is high among people living with HIV (PLWH). Data on the recently proposed definition of metabolic dysfunction-associated fatty liver disease (MAFLD) in PLWH receiving antiretroviral therapy (ART) remains unknown. A total of 282 PLWH were included in this cross-sectional cohort study. Vibration-controlled transient elastography (VCTE) was used to assess hepatic steatosis and fibrosis. MAFLD and its subgroups (overweight/obese, lean/normal weight, and type 2 diabetes) were defined according to a recently published international consensus statement. The majority of this cohort was male (n = 198, 70.2%), and the median age was 51.5 years. The median BMI was 25 kg/m
Identifiants
pubmed: 37280241
doi: 10.1038/s41598-023-32965-y
pii: 10.1038/s41598-023-32965-y
pmc: PMC10244325
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
9158Informations de copyright
© 2023. The Author(s).
Références
Hepatology. 2016 Jul;64(1):73-84
pubmed: 26707365
AIDS. 2017 Jul 17;31(11):1621-1632
pubmed: 28398960
Expert Rev Gastroenterol Hepatol. 2019 Jul;13(7):643-650
pubmed: 31081390
J Hepatol. 2016 Jun;64(6):1388-402
pubmed: 27062661
Gastroenterology. 2015 Aug;149(2):389-97.e10
pubmed: 25935633
Curr HIV/AIDS Rep. 2020 Dec;17(6):601-614
pubmed: 32984925
J Acquir Immune Defic Syndr. 2019 Apr 1;80(4):e86-e94
pubmed: 30570529
N Engl J Med. 2017 Nov 23;377(21):2063-2072
pubmed: 29166236
Hepatology. 2020 Mar;71(3):808-819
pubmed: 31675427
Diabetes Res Clin Pract. 2022 Aug;190:109981
pubmed: 35798217
J Hepatol. 2018 Feb;68(2):305-315
pubmed: 29154965
Cureus. 2021 Oct 25;13(10):e19046
pubmed: 34858740
Gut. 2010 Sep;59(9):1265-9
pubmed: 20801772
J Infect Dis. 2011 Jun 15;203(12):1791-801
pubmed: 21606537
Ann Intern Med. 2021 Jun;174(6):758-767
pubmed: 33721521
Clin Gastroenterol Hepatol. 2019 Feb;17(3):543-550.e2
pubmed: 30012432
EClinicalMedicine. 2021 Sep 05;40:101116
pubmed: 34522873
J Hepatol. 2020 Jul;73(1):202-209
pubmed: 32278004
Gastroenterology. 2020 May;158(6):1611-1625.e12
pubmed: 32027911
Liver Int. 2020 Sep;40(9):2079-2081
pubmed: 32930521
Lancet Gastroenterol Hepatol. 2020 Apr;5(4):362-373
pubmed: 32027858
Am J Clin Nutr. 2022 Jun 7;115(6):1528-1534
pubmed: 35244676
AIDS. 2022 Oct 1;36(12):1665-1674
pubmed: 35849074
J Hepatol. 2021 Sep;75(3):659-689
pubmed: 34166721
Liver Int. 2020 Sep;40(9):2082-2089
pubmed: 32478487
Liver Int. 2020 Dec;40(12):3018-3030
pubmed: 32997882
BMC Gastroenterol. 2006 Nov 02;6:33
pubmed: 17081293
Clin Infect Dis. 2010 Sep 1;51(5):496-505
pubmed: 20673002
Gastroenterology. 2019 May;156(6):1717-1730
pubmed: 30689971
Hepatology. 2007 Apr;45(4):846-54
pubmed: 17393509
Int J STD AIDS. 2021 Mar;32(3):266-275
pubmed: 33334267
AIDS. 2022 Dec 1;36(15):2147-2152
pubmed: 35950941
Hepatol Commun. 2022 Jun;6(6):1457-1466
pubmed: 35122404
Hepatol Commun. 2022 Aug;6(8):2011-2021
pubmed: 35411570
Hepatology. 2003 Aug;38(2):518-26
pubmed: 12883497
Hepatology. 2010 Feb;51(2):454-62
pubmed: 20101745
Hepatology. 2022 Jun;75(6):1420-1428
pubmed: 34779535
J Gastroenterol Hepatol. 2021 Jun;36(6):1670-1678
pubmed: 33140878
Sci Rep. 2020 Apr 21;10(1):6736
pubmed: 32317646